A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group
E. Strahlman, R. Tipping and R. Vogel
Department of Clinical Research, Merck Research Laboratories, West Point, Pa., USA.
OBJECTIVE: To investigate the safety profile and efficacy of 2.0%
dorzolamide hydrochloride, when administered three times daily for up to 1
year, compared with that of 0.5% timolol maleate and 0.5% betaxolol
hydrochloride, each administered twice daily. In addition, the effect of
adding dorzolamide to the regimen of patients with inadequate ocular
hypotensive efficacy while they were receiving one of the two
beta-adrenoceptor antagonists and the effect of adding timolol to the
regimen of patients receiving dorzolamide were also evaluated. DESIGN: A
double-masked, randomized, parallel comparison. SETTING: Multinational
study at 34 international sites. PATIENTS: Five hundred twenty-three
patients with open-angle glaucoma or ocular hypertension, 17 to 85 years of
age. Patients currently using ocular hypotensive medications were required
to undergo a washout. INTERVENTION: Two percent dorzolamide three times a
day, 0.5% timolol (Timoptic, Merck, Whitehouse Station, NJ) twice daily,
and 0.5% betaxolol solution (Betoptic, Alcon, Fort Worth, Tex) twice daily.
RESULTS: At 1 year, the mean percent reduction in intraocular pressure at
peak of 2% dorzolamide, 0.5% timolol, and 0.5% betaxolol was approximately
23%, 25%, and 21%, respectively. At afternoon trough, the mean percent
reduction in intraocular pressure was 17%, 20%, and 15% for dorzolamide,
timolol, and betaxolol, respectively. CONCLUSIONS: The ocular hypotensive
efficacy of 2.0% dorzolamide, given three times a day, is comparable with
that of 0.5% betaxolol, given twice daily, for up to 1 year. In addition,
long-term use of dorzolamide was not associated with clinically meaningful
electrolyte disturbances or systemic side effects commonly observed with
the use of oral carbonic anhydrase inhibitors.
A Randomized Trial Assessing Dorzolamide in Patients With Glaucoma Who Are Younger Than 6 Years
Ott et al.
Arch Ophthalmol 2005;123:1177-1186.
ABSTRACT
| FULL TEXT
Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension
Sharpe et al.
Br. J. Ophthalmol. 2004;88:953-956.
ABSTRACT
| FULL TEXT
Periorbital dermatitis as a side effect of topical dorzolamide
Delaney et al.
Br. J. Ophthalmol. 2002;86:378-380.
ABSTRACT
| FULL TEXT
Effect of Timolol, Latanoprost, and Dorzolamide on Circadian IOP in Glaucoma or Ocular Hypertension
Orzalesi et al.
IOVS 2000;41:2566-2573.
ABSTRACT
| FULL TEXT
A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study
O'Donoghue and the UK and Ireland Latanoprost Study Group
Br. J. Ophthalmol. 2000;84:579-582.
ABSTRACT
| FULL TEXT
Additive Effect of Dorzolamide on Aqueous Humor Flow in Patients Receiving Long-term Treatment With Timolol
Wayman et al.
Arch Ophthalmol 1998;116:1438-1440.
ABSTRACT
| FULL TEXT
Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study
Hutzelmann et al.
Br. J. Ophthalmol. 1998;82:1249-1253.
ABSTRACT
| FULL TEXT
A Double-Masked, Randomized, 1-Year Study Comparing the Corneal Effects of Dorzolamide, Timolol, and Betaxolol
Lass et al.
Arch Ophthalmol 1998;116:1003-1010.
ABSTRACT
| FULL TEXT
{beta}-Blocker-Induced Complications and the Patient With Glaucoma: Newer Treatments to Help Reduce Systemic Adverse Events
Stewart and Garrison
Arch Intern Med 1998;158:221-226.
FULL TEXT
Aqueous Humor Flow in Human Eyes Treated With Dorzolamide and Different Doses of Acetazolamide
Larsson and Alm
Arch Ophthalmol 1998;116:19-24.
ABSTRACT
| FULL TEXT
The management of primary open angle glaucoma
DTB 1997;35:4-6.
ABSTRACT
| FULL TEXT
